SCPX Bathi saben saham sajrone rolas wulan pungkasan NightHawk Biosciences

Scorpius Holdings, Inc. (SCPX) maintains operational resilience through its proprietary CDMO facility in Texas, which, combined with the defensive nature of the biopharmaceutical cycle, ensures stable demand. The rolling 12-month EPS captures this trend, with -101.97 representing the latest metric reading. However, intense competition within the biologics contract manufacturing sector forces the company to constantly compete for major clients.
Rincian metrik lan analitis perusahaan NightHawk Biosciences (SCPX)

To objectively evaluate an issuer, a manager requires earnings stripped of volatility. The EPS TTM metric aggregates net income over the last four quarters, dividing it by the total number of shares. By analyzing the annual net income per share trend, an investor determines the actual efficiency of capital generation. For Scorpius Holdings, Inc. (SCPX), this reflects financial stability amid steady demand for contract research. The dynamics of this metric here depend directly on the funding volumes of biotechnology clients.